Capvizr
News · All summaries
Healthcare & Life Sciences
Huasaibio
Series B$30 million
RoundSeries B
Amount$30 million
LeadSalvage Therapy
HQShanghai, China
DateNovember 9, 2026
THE DEAL, AT A GLANCE

Huasaibio

From the announcement
Cell therapy development
What it does] HUASAIBIO, established in March 2019, is a biopharmaceutical company dedicated to the development of novel innovative cell therapies.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Who is involvedBacked by Salvage TherapyFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
What happenedHuasaibio raised $30M Series B, announced 2026-11-09From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Why it mattersHuasaibio's $30M Series B adds to funding activity classified as Unclassified in the Capvizr database.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Huasaibio · Financing Record

Explore source-linked visual explanations for Huasaibio. Unsupported claims are withheld while source review continues.

Record 15676 · Recorded date: 2026-11-09

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime